Carlos Puig Duran

USPTO Granted Patents = 19 (Patent Applications = 7)

CIPO Patents = 7 (Patent Applications = 1)

EPO Patents = 12 (Patent Applications = 20)

Average Co-Inventor Count = 4.4

ph-index = 5

Forward Citations = 77(Granted Patents)

Location History:

Barlceona, ES (2009)
Barcelona, ES (2009 - 2019)
Sant Feliu de Llobregat, ES (2017 - 2019)

Company Filing History:

Laboratorios Almirall, S.a.

patents

1 out of 2

Laboratories Almirall, S.a.

patents

Years Active: 2009-2019

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10456390 - Combinations comprising MABA compounds and corticosteroids (2019-10-29),

2. 10300072 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2019-05-28),

3. 10005771 - Bicyclic derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2018-06-26),

4. 9757383 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2017-09-12),

5. 9643961 - Cyclohexylamine derivatives having β2 adrenergic antagonist and M3 muscarinic antagonist activities (2017-05-09),

6. 9579316 - Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both muscarinic receptor antagonist and β2 adrenergic receptor agonist activities (2017-02-28),

7. 9562039 - Salts of 2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one derivatives having both β2 adrenergic receptor agonist and M3 muscarinic receptor antagonist activities (2017-02-07),

8. 9549934 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2017-01-24),

9. 9518050 - Cyclohexyl and quinuclidinyl carbamate derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activity (2016-12-13),

10. 9315463 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2016-04-19),

11. 9233108 - Cyclohexylamine derivatives having β2 adrenergic agonist and M3 muscarinic antagonist activities (2016-01-12),

12. 8563731 - Mesylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]jamino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor (2013-10-22),

13. 8420669 - Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the BETA2 adrenergic receptor (2013-04-16),

14. 8283342 - Napadisylate salt of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one as agonist of the β2 adrenergic receptor (2012-10-09),

15. 8242177 - Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the β2 adrenergic receptor (2012-08-14),

Title: The Innovative Journey of Inventor Carlos Puig Duran

Introduction:

Carlos Puig Duran, a prolific inventor based in Barcelona, Spain, has made significant contributions to the field of pharmaceuticals with his groundbreaking patents and innovative research.

Latest Patents:

1. Combinations Comprising MABA Compounds and Corticosteroids: Introducing a novel combination of corticosteroid and a dual muscarinic antagonist-β2 adrenergic agonist compound for pharmaceutical use.

2. Cyclohexylamine Derivatives with β2 Adrenergic Agonist and M3 Muscarinic Antagonist Activities: Inventor of compounds with dual activity as a β2 adrenergic agonist and M3 muscarinic antagonist, revolutionizing respiratory therapies.

Career Highlights:

Carlos Puig Duran has amassed an impressive total of 19 patents throughout his career, showcasing his expertise and dedication to innovation in the pharmaceutical industry. His relentless pursuit of novel solutions has led to advancements in respiratory treatments and pharmaceutical compositions.

Collaborations:

Having collaborated with esteemed companies such as Almirall, S.A. and Laboratorios Almirall, S.A., Carlos Puig Duran has worked alongside notable colleagues like Jose Aiguade Bosch and Silvia Gual Roig. These partnerships have played a pivotal role in bringing his inventions to fruition and making a lasting impact on the field of pharmaceutical research.

Conclusion:

In conclusion, Carlos Puig Duran's inventive spirit and ingenuity have propelled him to the forefront of pharmaceutical innovation. His remarkable portfolio of patents stands as a testament to his unwavering commitment to advancing healthcare and improving patient outcomes. Barcelona can proudly claim Carlos Puig Duran as one of its visionary inventors shaping the future of medicine.

This text is generated by artificial intelligence and may not be accurate.